title: The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.
abstract: Breast cancer is the second most common cancer among American women and has a high rate of metastasis to bone. Patients regularly undergo adjuvant therapy (chemotherapy or hormonal therapy) following surgical resection of the tumor. In addition to potential direct effects on bone cells, both chemotherapy and hormonal therapy induce ovarian dysfunction and dramatically decrease estrogen levels in both pre- and postmenopausal women. This leads to decreased bone mineral density and increased fracture risk. Antiresorptive therapies (e.g, zoledronic acid and denosumab) have demonstrated efficacy in preventing cancer therapy-induced bone loss in patients with breast cancer and are approved for the prevention of skeletal-related events in patients with bone metastases from breast cancer. This review will focus on the evolving role of these antiresorptive therapies in the care of women with early or metastatic breast cancer.
authors: Department of Internal Medicine, UNM Cancer Center, 1 University of New Mexico, MSC 07-4025, Albuquerque, NM 87131-0001, USA.
authors: Dulcinea
authors: D
authors: Candelaria-Quintana
authors: Zoneddy R
authors: ZR
authors: Dayao
authors: Melanie E
authors: ME
authors: Royce
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D001862:Bone Resorption / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents